Thalidomide, an antiangiogenic agent with clinical activity in cancer

Biomedicine and Pharmacotherapy

Volumn 56, Issue 4, 2002, Pages 194-199

  Ng, S S W ^a   Brown, M ^a   Figg, W D ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

bFGF; HIV infection; Thalidomide; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; DOCETAXEL; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; BEHCET DISEASE; CANCER SURVIVAL; CHEMICAL TERATOGENESIS; CLINICAL TRIAL; CONGENITAL MALFORMATION; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SCREENING; DRUG WITHDRAWAL; GLIOMA; HUMAN; IMMUNOMODULATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LIVER CELL CARCINOMA; MONOTHERAPY; NONHUMAN; PREGNANCY; PRESCRIPTION; PRIORITY JOURNAL; REVIEW; TERATOGENICITY; TOXICITY; TUBERCULOSIS; TUMOR VASCULARIZATION; ANIMAL; CHEMISTRY; METABOLISM; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); STATISTICS;

ANGIOGENESIS INHIBITORS; ANIMAL; CLINICAL TRIALS; HUMAN; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; THALIDOMIDE; ANIMALS; HUMANS;

EID: 0035985945     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(02)00177-4     Document Type: Review

References (45)

1. Thalidomide is an inhibitor of angiogenesis
2. Mechanism of action in thalidomide teratogenesis
3. Thalidomide and congenital abnormalities
4. Thalidomide and congenital abnormalities
5. Potential novel uses of thalidomide: Focus on palliative care
6. Thalidomide in oncology: The peril and the promise
7. Thalidomide induced cessation of weight loss and improved sleep in advanced cancer patients with cachexia
8. Thalidomide for distressing night sweats in advanced malignant disease
9. Thalidomide for night sweats in patients with advanced cancer
10. Thalidomide in the treatment of plasma cell malignancies
11. Randomized phase II study of thalidomide in androgen-independent prostate cancer (AIPC)
12. Tumor angiogenesis: Therapeutic implications
13. Clinical applications of research on angiogenesis
14. Angiogenesis in cancer, vascular, rheumatoid and other diseases
15. Patterns and emerging mechanisms of angiogenic switch during tumorigenesis
16. Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization
17. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent
18. Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes
19. Thalidomide exerts its inhibitory action on tumor necrosis factor α by enhancing mRNA degradation
20. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the antitumor agent 5,6-dimethylxanthenone-4-acetic acid: Concomitant reduction of serum tumor necrosis factor-alpha and enhancement of antitumor activity
21. Binding of thalidomide to α1-acid glycoprotein may be involved in its inhibition of tumor necrosis factor production
22. The revitalization of thalidomide
23. Thalidomide: Current and potential clinical applications
24. Hypothesis: Thalidomide embryopathy-proposed mechanism of action
25. + subset
26. Thalidomide increases the synthesis of IL-2 in cultures of human mononuclear cells stimulated with concanavalin-A, staphylococcal enterotoxin A, and purified protein derivative
27. IgG antibody subclasses, tumor necrosis factor and IFN gamma levels in patients with type II lepra reaction on thalidomide treatment
28. Differential regulation by thalidomide and dexamethasone of cytokine expression in human peripheral blood mononuclear cells
29. Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity
30. Pharmacokinetics of thalidomide in an elderly prostate cancer population
31. Thalidomide metabolism by CYP2C subfamily
32. Research on thalidomide in solid tumors, hematological malignancies, and supportive care
33. Activity of thalidomide in AIDS-related Kaposi's sarcoma
34. Long-term follow-up of 169 patients in a phase II trial of single-agent thalidomide for advanced and refractory multiple myeloma
35. Thalidomide in the treatment of relapsed multiple myeloma
36. A phase II trial of thalidomide in the treatment of relapsed multiple myeloma with laboratory correlative studies
37. Anagnostopoulos, thalidomide and dexamethasone combination for refractory multiple myeloma
38. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
39. Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide
40. Phase II trial of thalidomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC)
41. Continuous low-dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
42. The treatment of advanced renal cell cancer with high-dose oral thalidomide
43. A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer
44. A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen-independent prostate cancer